Morning@ContangoPhil
I would place SNT 6302 at the front closest to commercialisation . On the Complexity Matrix of medicine Dermal Application / Topical Creams require the least amount of trialing/ testing. in comparison to Ingestion, then Infusion / Intravenous , then implants.
What has intrigued me and frustrated me also is that Gary just casually mentioned "Fiona Wood is currently using SNT 6302 on burns Grafts" that deserves an ASX Announcement.
Now Fiona must feel incredibly confident to utilise a non approved treatment in the general populous outside of the Trialing Regime? some here may recall DXB had 40 GP's request that the Trial Patients stay on the treatment for Kidney/ liver scaring? as it demonstrated a beneficial outcome for the Trial Patients.. That is of huge risk to the Doctors who requested this..
In short SNT 6302 could gain regulatory permission with in a year especially on the data/ information that Fiona is currently Gathering ,,, there is NO Standard of Care Product for surgical incisions ,, If SNT 6302 has shown effect on historic scars from Injury, Damage, Tears , Impact wounds and burns just imagine how effective it will be on a perfect surgical incision utilising a scalpel....
And that's not even touching the cosmetic market of Plastic Surgery etc
IMHO this company is truly undervalued but market Messaging may be a contributing factor to the low Value... remember circa 52% is owned by Funds and Insto's, near 10% is owned by management so only roughly 38% is in the Public/ Retail hands....so management only need to convey progress really to the bigger holders....
all the best of luck to all Holders
I have to agree@kpax and I've been in Biotech for 25 years ,,SNT is undervalued ,,,, as long as the Market are Informed "well" moving forward SNT should run up to $200m MC ,,, heck there are some Phase I Parkinson companies alone that have $100M MC
Add to My Watchlist
What is My Watchlist?
